Drug Type Antibody drug conjugate (ADC) |
Synonyms- |
Target |
Action antagonists, inhibitors |
Mechanism CDH17 antagonists(Cadherin-17 antagonists), CLDN18.2 inhibitors(Claudin 18.2 inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Colorectal Cancer | Preclinical | China | 27 Apr 2025 | |
Colorectal Cancer | Preclinical | Hong Kong | 27 Apr 2025 | |
Pancreatic Ductal Adenocarcinoma | Preclinical | China | 27 Apr 2025 | |
Pancreatic Ductal Adenocarcinoma | Preclinical | Hong Kong | 27 Apr 2025 | |
Stomach Cancer | Preclinical | China | 27 Apr 2025 | |
Stomach Cancer | Preclinical | Hong Kong | 27 Apr 2025 |